Infusion of CARv3-TEAM-E T Cells in Glioblastoma. Reply

N Engl J Med. 2024 Jun 27;390(24):2330-2331. doi: 10.1056/NEJMc2405721.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bevacizumab / adverse effects
  • Bevacizumab / therapeutic use
  • Brain Diseases / drug therapy
  • Brain Diseases / etiology
  • Brain Neoplasms* / therapy
  • Clinical Trials, Phase I as Topic
  • Dexamethasone / therapeutic use
  • Glioblastoma* / therapy
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Receptors, Chimeric Antigen
  • T-Lymphocytes* / immunology

Substances

  • Receptors, Chimeric Antigen
  • Dexamethasone
  • Bevacizumab